Ionis Pharmaceuticals Inc
NASDAQ:IONS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.73
53.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Accounts Receivables
Ionis Pharmaceuticals Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
Accounts Receivables
$17.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$7.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
32%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$6.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
Ionis Pharmaceuticals Inc
Glance View
In the realm of pharmaceutical innovation, Ionis Pharmaceuticals Inc. has carved a niche defined by its pioneering efforts in antisense technology. Founded in 1989, Ionis stands as a trailblazer in the development of RNA-targeted therapies, which deviate from the traditional drug development pathways by focusing on genetic solutions. The company specializes in antisense oligonucleotides—short, synthetic strands of DNA or RNA designed to bind selectively to specific messenger RNA (mRNA). By doing so, they aim to modulate the expression of genes associated with various diseases. This unique approach allows Ionis to address ailments at the genetic level, potentially preventing the production of disease-causing proteins, thus offering alternative therapeutic options for serious diseases. Ionis Pharmaceuticals monetizes its scientific breakthroughs through a diverse revenue stream model. It engages in multiple collaborative partnerships with major pharmaceutical companies, such as Biogen and AstraZeneca, which provide upfront payments, milestone-based fees, and royalties on lucrative antisense drugs that emerge from these alliances. Furthermore, Ionis holds an extensive internal pipeline, advancing proprietary drugs through various stages of research and clinical trials. By strategically balancing in-house projects with external collaborations, Ionis capitalizes on its innovative platform while mitigating financial risks. This dual-strategy not only sustains the company financially but positions it at the forefront of personalized medicine, potentially revolutionizing the landscape of therapeutic development.
See Also
What is Ionis Pharmaceuticals Inc's Accounts Receivables?
Accounts Receivables
17.9m
USD
Based on the financial report for Sep 30, 2024, Ionis Pharmaceuticals Inc's Accounts Receivables amounts to 17.9m USD.
What is Ionis Pharmaceuticals Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
-4%
Over the last year, the Accounts Receivables growth was -87%. The average annual Accounts Receivables growth rates for Ionis Pharmaceuticals Inc have been 25% over the past three years , -18% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
